Antibody-Drug Conjugates Targeted at Human Aspartyl-(Asparaginyl)-B-Hydroxylase (HAAH)
AssigneePanacea Pharmaceuticals, Inc.
InventorsHossein Ghanbari, Steven A. Fuller, Michael Lebowitz, Zhi-Gang Jiang
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-HAAH antibodies and derivatives thereof conjugated to cytotoxic, cytostatic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods for the treatment of HAAH-expressing cancers, comprising administering to a subject the disclosed pharmaceutical compositions.
Claims20
An antibody-drug conjugate comprising an anti-HAAH monoclonal antibody conjugated to at least one cytotoxic or cytostatic drug, and optionally a linker connecting the antibody and the cytotoxic or cytostatic drug.
A method of making an antibody-drug conjugate comprising, conjugating at least one cytotoxic or cytostatic drug to an anti-HAAH antibody, and optionally conjugating a linker connecting the drug and the antibody.
Dependencies are inferred from the claim text.